{"nctId":"NCT01572740","briefTitle":"Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes","startDateStruct":{"date":"2012-04-05","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":257,"armGroups":[{"label":"Lira+Insulin","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide","Drug: insulin"]},{"label":"Placebo+Insulin","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo","Drug: insulin"]}],"interventions":[{"name":"liraglutide","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"insulin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months\n* Current insulin therapy (basal insulin, premixed insulin or basal-bolus regimen) in addition to diet and exercise therapy for at least 12 weeks prior to trial start. Their therapy is stable and fluctuation of total daily insulin dose is within plus/minus 20% for at least 12 weeks prior to trial start and current total daily insulin dose equal to or greater than 10 (I)U/day\n* Glycosylated haemoglobin (HbA1c) between 7.5 and 11.0% (both inclusive)\n* Body Mass Index (BMI) below 45.0 kg/m\\^2\n\nExclusion Criteria:\n\n* Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as, but not limited to systemic corticosteroids, beta-antagonists or monoamine oxidase (MAO) inhibitors\n* Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic episode during last 12 months) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months\n* Known proliferative retinopathy or maculopathy requiring treatment according to the investigator\n* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonist within 12 weeks prior to screening\n* Treatment with any oral antidiabetic drugs (OADs) within 12 weeks prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16","description":"Estimated mean change from baseline in HbA1c after 16 Weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.73","spread":"0.06"},{"groupId":"OG001","value":"-0.43","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 36","description":"Estimated mean change from baseline in HbA1c after 36 Weeks of treatment","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"0.06"},{"groupId":"OG001","value":"-0.88","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16","description":"Estimated mean change from baseline in FPG after 16 Weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":"0.17"},{"groupId":"OG001","value":"-0.48","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 36","description":"Estimated mean change from baseline in FPG after 36 Weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.55","spread":"0.16"},{"groupId":"OG001","value":"-1.29","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 16","description":"Estimated mean change from baseline in mean PG of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 16 Weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.41","spread":"0.18"},{"groupId":"OG001","value":"-0.53","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 36","description":"Estimated mean change from baseline in mean PG of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 36 Weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.65","spread":"0.16"},{"groupId":"OG001","value":"-1.37","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 16","description":"Estimated mean change from baseline in mean prandial PG increment of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 16 Weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.34","spread":"0.17"},{"groupId":"OG001","value":"-0.61","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 36","description":"Estimated mean change from baseline in mean prandial PG increment of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 36 Weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.34","spread":"0.21"},{"groupId":"OG001","value":"-0.94","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Week 16","description":"Estimated mean change in body weight after 16 Weeks of treatment","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"0.14"},{"groupId":"OG001","value":"-0.28","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Week 36","description":"Estimated mean change in body weight after 36 Weeks of treatment","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.20"},{"groupId":"OG001","value":"0.52","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events (AEs)","description":"An AE was defined as treatment emergent if the onset date was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"449","spread":null},{"groupId":"OG001","value":"350","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"436","spread":null},{"groupId":"OG001","value":"335","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Confirmed Hypoglycaemic Episodes","description":"A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and until the last day on randomised treatment. Confirmed hypoglycaemic episode was defined as hypoglycaemic episodes categorised to severe and/or minor hypoglycaemic episodes.\n\nConfirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded PG \\< 3.1 mmol/L (56 mg/dL). Minor: PG \\< 3.1 mmol/L (56 mg/dL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":127},"commonTop":["Nasopharyngitis","Diabetic retinopathy","Nausea","Diarrhoea","Constipation"]}}}